Performance of Unobserved Self-Collected Nasal Swabs for Detection of SARS-CoV-2 by RT-PCR Utilizing a Remote Specimen Collection Strategy

Ron M. Kagan¹, Amy A. Rogers¹, Gwynngelle A. Borillo¹, Nigel J. Clarke¹ and Elizabeth M. Marlowe¹

¹Quest Diagnostics Infectious Disease, San Juan Capistrano, CA USA

Corresponding Author: Elizabeth M. Marlowe, PhD, D(ABMM), SM(ASCP)
Senior Scientific Director, Head R&D West, Infectious Disease
Quest Diagnostic Infectious Disease
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042
Elizabeth.M.Marlowe@questdiagnostics.com
phone: 949-728-1817
fax: 949-728-7180

Alternate Corresponding Author: Ron M. Kagan, PhD
Senior Director of Bioinformatics, Molecular Infectious Disease
Quest Diagnostics, Infectious Disease
33608 Ortega Hwy
San Juan Capistrano, CA 92675
949-728-1882 (phone)
949-728-7180 (fax)
Ron.M.Kagan@questdiagnostics.com

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Summary: Unobserved self-collection of nasal swabs for SARS-CoV-2 RT-PCR performs as well as health care provider (HCP) collection of clinical specimens. Single-specimen Ct value distribution supports the use of more efficient pooled specimen testing for unobserved self-collected specimens.
Abstract

Background: The use of a remote specimen collection strategy employing a kit designed for unobserved self-collection for SARS-CoV-2 RT-PCR can decrease the use of PPE and exposure risk. To assess the impact of unobserved specimen self-collection on test performance, we examined results from a SARS-CoV-2 qualitative RT-PCR test for self-collected specimens from participants in a return-to-work screening program and assessed the impact of a pooled testing strategy in this cohort.

Methods: Self-collected anterior nasal swabs from employee return to work programs were tested using the Quest Diagnostics SARS-CoV-2 RT-PCR EUA. The Ct values for the N1 and N3 N-gene targets and a human RNase P (RP) gene control target were tabulated. For comparison, we utilized Ct values from a cohort of HCP-collected specimens from patients with and without COVID-19 symptoms.

Results: Among 47,923 participants, 1.8% were positive. RP failed to amplify for 13/115,435 (0.011%) specimens. The median (IQR) Cts were 32.7 (25.0-35.7) for N1 and 31.3 (23.8-34.2) for N3. Median Ct values in the self-collected cohort were significantly higher than those of symptomatic, but not asymptomatic patients. Based on Ct values, pooled testing with 4 specimens would have yielded inconclusive results in 67/1,268 (5.2%) specimens but only a single false-negative result.

Conclusions: Unobserved self-collection of nasal swabs provides adequate sampling for SARS-CoV-2 RT-PCR testing. These findings alleviate concerns of increased false negatives in this context. Specimen pooling could be used for this population as the likelihood of false negative results is very low due when using a sensitive, dual-target methodology.

Keywords: SARS-CoV-2, COVID 19, self-collection, RT-PCR, cycle threshold
BACKGROUND

The ongoing coronavirus disease 2019 (COVID-19) pandemic has placed unpredicted strains on the US healthcare system resulting in an extraordinary worldwide demand for laboratory testing. Nucleic acid amplification testing (NAAT) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from upper respiratory swabs is a critical tool for addressing the pandemic. The current U.S. Centers for Disease Control (CDC) Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html) include nasopharyngeal (NP) or oropharyngeal (OP) swabs collected by a healthcare provider (HCP) or nasal (mid-turbinate, anterior nares) swabs collected either by an HCP or self-collected (SC) by the patient either unsupervised at home or supervised onsite. Recent studies have shown that patient self-collected nasal swabs are comparable to HCP-collected swabs for SARS-CoV-2 testing. Self-collection of swab samples for SARS-CoV-2 testing may be beneficial to limit the use of personal protective equipment (PPE), reduce the risk of infection to healthcare workers and to other patients, and offer additional opportunities to provide services and decrease the burden in clinics. In addition, SARS-CoV-2 testing by RT-PCR utilizing unobserved self-collected nasal swabs is an important return to work tactic to help ensure a safe work environment, supporting the nation’s economic viability. As employees transition from a working from home model, they may undergo voluntary screening prior to returning to work. This demographic represents a low disease prevalence population and pooled RT PCR testing could afford a more efficient and rapid way to perform screening. In a previous study we demonstrated that pooled and individual testing of specimens positive for SARS-CoV-2 demonstrated 100% agreement. Quantitative comparisons between RT-PCR cycle threshold (Ct) values of internal adequacy controls have been used to evaluate differences in adequacy between HCP-collected and self-collected respiratory samples in a number of studies. In the current study, we examined the Ct value distribution of an Rnase P (RP) specimen adequacy control to further improve our understanding of the ability of patients to self-collect specimens utilizing an alternate...
delivery strategy. In addition, we examined the distribution of Ct values among unobserved self-collected nasal swabs to assess whether using pooled, rather than singlicate, testing would have increased the risk of false-negative test results.

**METHODS**

In this retrospective study, we tabulated the Ct values for a cohort of unobserved self-collected nasal swabs tested in singlicate between June and August 2020 using the Quest Diagnostics SARS-CoV-2 qualitative RT-PCR authorized for emergency use (EUA) by the US Food and Drug Administration (FDA) for self-collection. The test utilizes a one-step reverse transcription and PCR amplification with SARS-CoV-2 specific primers and real-time detection with SARS-CoV-2 specific probes for the N1 and N3 targets of the virus nucleocapsid gene. This test utilizes an in-house prepared exogenous N-gene transcript that served as an internal extraction and amplification control. For these unobserved self-collected specimens, an independent human RNAse P (RP) gene target to verify adequacy of nasal swab self-collection was included in the assay in a separate well (https://www.fda.gov/media/136231/download). Nasal swab self-collection was performed using an FDA EUA self-collection kit. Briefly, collection kits were mailed to participants with instructions to collect bilateral nasal swabs and specimens sent back to the testing laboratory via FedEx as described in the instructions for use (https://www.fda.gov/media/138402/download).

HCP-collected specimens were submitted to Quest Diagnostics from providers primarily the U.S. including from hospitals, health maintenance organizations and private practitioners. N1 and N3 Ct values for all SARS-CoV-2 positive HCP-collected specimens tested during the same period and selected from patients spanning the same range of ages as for the self-collected specimens were tabulated for comparison. Additionally, we tabulated Ct values for HCP-collected specimens that included an optional indication of whether the patient was symptomatic for COVID-19. These specimens were tested between March 24 and May 13, 2020 and selected from patients spanning
the same range of ages as for the self-collected specimens. HCP-specimen types included nasopharyngeal, oropharyngeal and nasal swabs as well as bronchoalveolar lavage, but were not recorded at the time of the test order submission.

A specimen was deemed positive for SARS-CoV-2 RNA if the Ct values for both targets were <40 cycles; negative if the Ct values for both targets were ≥40 cycles and the internal amplification control was valid; and inconclusive if the Ct value was <40 cycles for only one detector. Specimens with inconclusive results were retested in singlicate, from the original swab. In self-collected specimens that were negative for the SARS-CoV-2 N1 and N3 targets, the test was deemed invalid if the RP amplification was not evident (Ct value ≥40) in the initial test run and upon repeat. Patient age, gender and Ct values for N1, N3 and RP were tabulated in a database and the distributions of Ct values were evaluated and compared to the shift in the Ct value cutoff determined for pooled testing (40 cycles – Ctshift) using the Quest SAR-CoV-2 RT-PCR EUA assay.

Statistical analysis was performed using Analyze-it for Microsoft Excel, version 5.65.9. Proportions were compared with the Pearson chi-squared test. Continuous variables were compared with the Kruskal-Wallis test or the Wilcoxon-Mann-Whitney test. The Hodges-Lehmann estimator was used to estimate median Ct value shifts and the 95% confidence interval.

**Patient Consent Statement**

This study utilized retrospectively collected, de-identified data from previously tested specimens. No human subjects were utilized in this study and thus patient consent was not applicable.
RESULTS

We tabulated SARS-CoV-2 RT-PCR results from 115,435 specimens obtained by unsupervised self-collection from 47,923 participants (men: 70.6%) and reported between June 3 and August 12, 2020. Fifty percent of the participants in this cohort submitted a single specimen, 12.3% submitted two specimens, 10.5% submitted three specimens and 27.3% submitted ≥4 specimens (maximum: 9). The median Ct value for the RP sampling adequacy target was 23.0 for the positive and 23.4 for the negative specimens, and the 99.5th percentile for RP Ct values was <30, indicating adequate nasal swab sampling for the vast majority of specimens (Table 1). The 99.5th percentile of the RP Ct values for 110 specimens with an inconclusive report was also <30, indicating adequate sampling independent of an inconclusive SARS-CoV-2 test result. The coefficient of variation (CV) of RP Ct values for 18,083 patients with ≥3 test results was 5.2% ± 2.9% (SD), indicating relative uniformity of intra-patient specimen self-collection. Invalid results were obtained for 13 specimens (0.011%) from 13 participants; these specimens did not show RP amplification despite positive amplification of the specimen internal RT-PCR control. Subsequent testing was performed for 8/13 participants and yielded negative SARS-CoV-2 results. There were no significant differences in RP Ct values between SARS-CoV-2 positive and negative specimens (data not shown).

The overall SARS-CoV-2 positivity rate (95% CI) for this cohort was 1.8% (1.7%-1.9%). The positivity rate was higher for women than for men, (p<0.0001; Table 2). Twenty seven percent (234/859) of the SARS-CoV-2 positive patients had two or more SARS-CoV-2 positive results. The median (IQR) number of days between the first and the last positive result was 11 (7-15) with a maximum of 36 days for all but a single outlier tested again 110 days after the first test. We excluded 6 patients who were tested twice on the same day or only one day apart between the first and the last test. The Hodges-Lehmann estimators for the median (95% CI) increase in the Ct values between the first and the last positive test were 9.4 (8.3-10.4) for the N1 target and 9.0 (7.9-10.1) for N3 (Figure 1a,b). Overall, the median Ct values for the SARS-CoV-2 nucleocapsid gene targets N1 and N3 were 32.7 and 31.3, respectively, for 1,268 positive specimens (Table 3) and did not vary...
significantly by patient age or by gender (Supplemental Material, Figures S1 and S2). Median RP Ct values showed small variations by age group, ranging from 22.6 to 23.3 (p=0.016, Figure S3) as well as by gender, with median Ct values of 23.2 for women and 22.8 for men (Figure S4, Hodges-Lehmann shift: 0.5 [0.3 – 0.7] Cts; p<0.0001).

Ct values for HCP-collected clinical specimens tested during the same time period were considerably lower than those for the SC cohort with medians of 23.6 for N1 and 22.5 for N3 (Table 3). We also compared the Ct values from the SC and HCP-collected specimens to Ct values from patients who were indicated to be symptomatic or asymptomatic for COVID-19 on the test requisition; these specimens were tested during an earlier time period, when this indication was optionally provided at the time of test order placement. The median N1 and N3 Ct values for the specimens from the asymptomatic patients were not significantly different (N1: p=0.29; N3: p=0.39) than those from the SC cohort (Table 3). In contrast, the median N1 and N3 Ct values from the symptomatic patients were significantly lower (p<0.0001) than those for the SC group, and similar to those for the contemporarily HCP-collected clinical specimens (Table 3).

Previously, we described a SARS-CoV-2 pooled testing strategy to test four specimens in a single pool to increase testing efficiency and conserve testing resources. When a single SARS-CoV-2 positive sample is pooled with three negative samples there is a small loss of detection sensitivity manifested as average Ct value shifts of 2.4 and 1.9 for the N1 and N3 targets respectively, and the upper Ct cutoff for a positive result is then defined as 40 – Ct_shift. To assess whether pooled testing could also be effective for unsupervised self-collected specimens without appreciable loss of sensitivity, we evaluated the effect of the pooled Ct value shift on the positive specimens in the current study. We found that 67 specimens (5.3% of the positives) had an N1 target Ct value greater than the pool-shifted Ct of 37.6 for N1 (Table 3). However, a single specimen had an N3 target Ct value greater than the pool-shifted Ct value of 38.1 for N3 and the N1 Ct for this specimen was 39.2. Thus, had pooled testing been utilized for these 1,268 positive specimens, it is estimated that it would have resulted in only a single false-negative report and 66 inconclusive results, which would
have necessitated repeat singlicate testing from the original specimen. Similarly low proportions (0.0%-0.15%) of Ct values for HCP-collected clinical specimens that had N3 Ct values greater than the pool-shifted Ct value (Table 3).

**DISCUSSION**

In this retrospective study of over 47,000 individuals undertaking SARS-CoV-2 screening, unobserved self-collection of nasal swabs resulted in highly reproducible RP control Ct values with low inter-patient variability. RP Ct values were less than 30 cycles for the vast majority of patients, indicating that unobserved self-collection is able to provide adequate swab samples for RT-PCR testing. The distribution of RP Ct values also did not vary between individuals with positive, negative, or inconclusive SARS-CoV-2 results. These findings alleviate concerns of increased false negatives in the context of unobserved self-collection for SARS-CoV-2 screening. Similar results have been found in other self-collection studies. In a study by Akmatov et al, the detection of a respiratory viral pathogen was found to be independent of the DNA concentration of a β-actin internal adequacy control for both self-collected and staff-collected swabs. The overall positivity rate for this screening population was low (<2%), and a higher percentage of women than men had positive test results. In contrast, the positivity rate for clinical HCP-ordered tests tested over the same period in our laboratory was nearly the same for men and women (9.7% and 9.9%, respectively). The reason for this sex difference in positivity rates in the self-collection cohort could not be ascertained, however, it could be speculated that women in this cohort assumed a larger proportion of tasks such as grocery shopping and child care that put them at a higher risk for exposure to COVID-19.

Overall, 27% (N3 target) to 41% (N1 target) of the self-collected specimens had Ct values ≥33, representing lower viral loads in the specimens. For the 25% of patients with positive results who were serially tested in the self-collection cohort, Ct values from the last RT-PCR test obtained a
median of 11 days after the first test had median Ct values of 33-34, a median of 9 Cts higher than the values obtained for the first positive test result (Figure 1). This increase in Ct values in serially tested specimens likely represents a decline in viral shedding. Likewise, higher Ct values were seen for a set of HCP-ordered clinical specimens for patients indicated to be asymptomatic at the time of testing. In contrast, the median N1 and N3 Ct values from the symptomatic patients were significantly lower than those for the self-collection cohort, and more similar to the contemporary HCP-collected clinical specimens (Table 3). We found that Ct values were significantly higher in the self-collected and the asymptomatic cohorts. In prior work, asymptomatic patients have been shown to have viral loads comparable to those of symptomatic patients. However, in one study of SARS-CoV-2 viral loads in asymptomatic and symptomatic children in pediatric hospitals, it was found that the adjusted median Cts for asymptomatic children were 10.3 Cts higher than for symptomatic children and the viral load was 3-4 logs lower. The authors noted that asymptomatic patients with a recent known COVID-19 contact were more likely to have a higher viral load and postulate that the lower viral loads in the pre-procedure/pre-admission testing groups likely reflected remote infections. In contrast, many of the studies of viral load level differences between asymptomatic and symptomatic adults involved well-defined cohorts with recent exposure.

Although data are not available for the timing of exposure for the cohorts in our study, it is plausible that differential exposure timing could account for these differences. Symptomatic patients are more likely to present during the window when the viral load is high. As noted among the serially-tested self-collected specimens, the Ct difference between the first positive and last positive test was a median of 9 Cts (Figure 1). In light of our findings, it is critical to understand the impact of the diluted pooled testing on the ability to provide accurate results when applying a pooled testing approach among asymptomatic patients.

In previous work, we showed that pooling one positive and three negative HCP-collected clinical specimens from populations with a SARS-CoV-2 prevalence of ≤ 10% does not increase the false-negative rate for RT-PCR testing. In the current study we compared the self-collected
specimen Ct values to the pool-shifted Ct values. Despite the higher median Ct values for this cohort, only a single specimen out of 1,268 self-collected specimens could potentially have yielded a false negative result in a pooled testing approach. An additional 67 specimens (5.3%) would have produce an inconclusive result which would have then triggered single testing of the pooled specimens resulting in 268 single tests. We again found that the low false-negative rate could be attributed to the use of a dual-target RT-PCR system that included the more sensitive N3 target. As the SARS-CoV-2 positivity rate for self-collected screening samples in return to work programs was low (1.8%), pooling could be utilized efficiently to reduce utilization of testing supplies and reagents while increasing laboratory testing throughput. Further gains in testing efficiency could be achieved by increasing the pool size from four specimens to eight, as recommended for maximizing pooled testing efficiency at this low prevalence (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised). The effects of a larger pool size on assay sensitivity and the false-negative rate would need to be carefully assessed.

Our study had several limitations. First, for the majority of patients no clinical information was available. Although most patients who are participating in a return to work SARS-CoV-2 testing program are likely to be asymptomatic, we cannot verify this claim. However, several lines of evidence suggest that most employees providing self-collected specimens were asymptomatic: (1) median Ct values were significantly higher in the self-collected specimens than in the HCP-collected clinical specimens tested over the same period, suggesting that they were drawn from different populations; (2) the median N1 and N3 Ct values in the self-collection cohort was significantly higher than the respective Ct values among patients indicated to be symptomatic at the time of testing; and (3) the median N1 and N3 Ct values in the self-collection cohort did not differ significantly from of the respective Ct values for patients indicated to be asymptomatic at the time of testing.

Second, because this study was retrospective, we were unable to fully evaluate the performance of these specimens in pooled testing, as they were no longer available. Instead, we
were able to estimate the performance of these specimens in pooled testing based on the reported single-specimen testing Ct values compared to the pool-shifted Ct values determined previously. In-house validation studies have demonstrated reproducible Ct Shifts with a four specimen Dorfman pooling scheme (data not shown). A prospective study would be needed to validate pooling for this population or to validate the use of a larger pool size to maximize testing efficiency.

Third, an RP internal adequacy control was not used for HCP-collected specimens and thus we were unable to utilize RP Cts to evaluate potential differences between HCP-collection and self-collection. As a control we randomly tested specimens that had been HCP collected and found that they demonstrated similar RP Ct values to self-collected specimens (data not shown). Based on the literature, Akmatov et al found that the median β-actin adequacy control DNA concentration was higher in self-collected vs staff-collected nasal swabs for respiratory pathogen detection. Thompson et al found that the mean RP Ct for self-collected nasal swabs used for influenza detection in pregnant women was significantly higher than the mean Ct for staff-collected nasopharyngeal swabs in an earlier study however the magnitude of the difference was modest (26.5 vs 24.1) and all specimens were adequate. Arnold et al compared the adequacy of participant-collected midturbinate or anterior nasal swabs vs staff-collected oropharyngeal swabs and again found that participant-collected swabs had modestly higher Cts, but overall adequacy for participant-collected nasal specimens was 96.4%. These findings alleviate the concern that the self-collected specimens in the current study had a higher SARS-CoV-2 false negative rate than HCP-collected specimens.

Fourth, the specimen types for the HCP-collected specimens included a mix of specimen types and transport media, including nasal, nasopharyngeal and oropharyngeal swabs as well as other specimens. That information was not collected for the HCP specimens during the study period, therefore we were unable to control for these factors when comparing the median Cts in HCP-collected specimens vs the self-collected nasal swab specimens. However, a recent review and meta-analysis found that the positive percent agreement in detection rates between nasal swab
samples and a variety of index samples was high across a range of studies. Tu et al found that there was a good correlation between Cts for patient-collected nasal swabs and provider-collected NP swabs and noted that the Cts for the nasal swabs were lower than the Cts for the NP swabs in 50% of the cases and suggested that the viral loads in the nose and the nasopharynx may be equivalent.

Fifth, the cohort in this study consists primarily of working-age adults employed by major corporations with over 80% employed in the technology sector. The literacy rate may be higher in this group compared to the general population, reflecting on their ability to follow directions for self-collection and packaging and shipping of their specimens. For example, a study of 135 patients who self-collected swab samples for respiratory virus surveillance found that 13% of the participants made one or more packing errors when shipping the specimens. Therefore, the high degree of adequate sampling we reported for the present cohort may not be generalizable to other diverse cohorts. However, our results were consistent with the patient usability study that was required for the EUA of an unobserved self-collection kit which included a diverse cohort of patients (https://www.fda.gov/media/136231/download).

Lastly, the SARS-CoV-2 RT-PCR assay utilized in this study is a qualitative assay and not a quantitative assay for assessing viral load. Caution should be used when evaluating Ct values. While Ct values have been examined in a semi-quantitative manner, it remains to be determined how Ct values correlate with transmission. Cell culture studies have shown that infectious virus is rarely isolated from individuals with viral loads <10^5 copies/mL. It is unclear if these patients no longer harbored infectious virus at the viral loads represented by these Ct values and potentially representing a low transmission risk. Further studies are warranted to understand the dynamics of asymptomatic transmission. For a summary of duration and infectivity studies see Rhee et al.
In summary, we have demonstrated that unobserved self-collection of nasal swabs for SARS-CoV-2 does not increase the risk of false-negative results. This approach may be a good strategy for conserving PPE and minimizing risks of transmission to HCPs, patients, and screening participants. We further demonstrated that a more efficient pooled testing strategy could be used for this population as the likelihood of false-negative results is very low due to the use of a sensitive, dual-target RT-PCR test.
ACKNOWLEDGMENTS

Financial support. This work was supported by Quest Diagnostics Incorporated (Secaucus, NJ USA).

Potential conflicts of Interest. All authors of this manuscript are employees of Quest Diagnostics Incorporated (Secaucus, NJ USA), a diagnostics laboratory that provides SARS-CoV-2 testing.
References

1. Tu YP, Jennings R, Hart B, et al. Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing. *N Engl J Med.* Jul 30 2020;383(5):494-496.
2. McCulloch DJ, Kim AE, Wilcox NC, et al. Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 Infection. *JAMA Netw Open.* Jul 1 2020;3(7):e2016382.
3. Wehrhahn MC, Robson J, Brown S, et al. Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic. *J Clin Virol.* Jul 2020;128:104417.
4. Hanson KE, Barker AP, Hillyard DR, et al. Self-Collected Anterior Nasal and Saliva Specimens versus Healthcare Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2. *J Clin Microbiol.* Aug 12 2020.
5. Borillo GA, Kagan RM, Baumann RE, et al. Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing. *Open Forum Infectious Diseases.* 2020;7(11).
6. Akmatov MK, Gatzemeier A, Schughart K, Pessler F. Equivalence of self- and staff-collected nasal swabs for the detection of viral respiratory pathogens. *PLoS One.* 2012;7(11):e48508.
7. Arnold MT, Temente JL, Barlow SK, et al. Comparison of participant-collected nasal and staff-collected oropharyngeal specimens for human ribonuclease P detection with RT-PCR during a community-based study. *PLoS One.* 2020;15(10):e0239000.
8. Thompson MG, Ferber JR, Odouli R, et al. Results of a pilot study using self-collected mid-turbinate nasal swabs for detection of influenza virus infection among pregnant women. *Influenza Other Respir Viruses.* May 2015;9(3):155-160.
9. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of SARS-CoV-2 Infectivity: When is it Safe to Discontinue Isolation? *Clinical Infectious Diseases.* 2020.
10. Jackson ML, Nguyen M, Kirlin B, Madziwa L. Self-Collected Nasal Swabs for Respiratory Virus Surveillance. *Open Forum Infect Dis.* Dec 2015;2(4):ofv152.
11. Quicke K, Gallichote E, Sexton N, et al. Longitudinal Surveillance for SARS-CoV-2 RNA Among Asymptomatic Staff in Five Colorado Skilled Nursing Facilities: Epidemiologic, Virologic and Sequence Analysis. *medRxiv.* Jun 9 2020.
12. Huff HV, Singh A. Asymptomatic transmission during the COVID-19 pandemic and implications for public health strategies. *Clin Infect Dis.* May 28 2020.
13. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med.* Mar 19 2020;382(12):1177-1179.
14. Kociolek LK, Muller WJ, Yee R, et al. Comparison of upper respiratory viral load distributions in asymptomatic and symptomatic children diagnosed with SARS-CoV-2 infection in pediatric hospital testing programs. *J Clin Microbiol.* Oct 22 2020.
15. Comber L, Walsh KA, Jordan K, et al. Alternative clinical specimens for the detection of SARS-CoV-2: A rapid review. *Rev Med Virol.* Oct 22 2020.
16. Rhoads D, Peaper DR, She RC, et al. College of American Pathologists (CAP) Microbiology Committee Perspective: Caution must be used in interpreting the Cycle Threshold (Ct) value. *Clin Infect Dis.* Aug 12 2020.
17. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis.* Jun 2020;39(6):1059-1061.
### Table 1: RNase P Ct Value Distributions for Self-Collected SARS-CoV-2 Positive, Negative, and Inconclusive Specimens

| Group        | N     | Median Ct (IQR)       | 99.5th percentile of RP Ct values |
|--------------|-------|-----------------------|-----------------------------------|
| Positive     | 1,268 | 23.0 (21.8-24.1)      | 29.4                              |
| Negative     | 114,057 | 23.4 (22.2-24.7)    | 29.8                              |
| Inconclusive | 110   | 23.1 (21.9-24.3)      | 27.6                              |

*a See Methods for the criteria used to classify test results as positive, negative, or inconclusive.*
Table 2: Participant Demographics and SARS-CoV-2 Positivity Rates for Self-Collected Specimens

| Group      | Participants<sup>a</sup> | Age median (IQR) |
|------------|--------------------------|------------------|
|            | All                      | F                | M                | F         | M         |
| Positive   | 859                      | 330              | 529              | 28.0      | 30.0      |
|            |                          |                  |                  | (24.0-36.0) | (25.0-39.0) |
| Negative   | 47048                    | 13,763           | 33,285           | 32.0      | 32.0      |
|            |                          |                  |                  | (26.0-44.0) | (24.0-44.0) |
| Inconclusive | 16                      | 6                | 10               | -         | -         |
| Total      | 47,923                   | 14,099           | 33,824           | -         | -         |

| Positivity rate (95% CI)<sup>c</sup> |
|--------------------------------------|
| 1.8 (1.7-1.9)                       |
| 2.3 (2.1-2.6)                       |
| 1.6 (1.4-1.7)                       |

<sup>a</sup> N=47,923 unique participants tested one to nine times from a total of 115,422 specimens with a positive, negative or inconclusive result.

<sup>b</sup> Positive participants had at least one positive SARS-CoV-2 test result. Negative participants were defined as those who never had a positive result. Inconclusive patients had only an inconclusive test result as defined in Materials and Methods.

<sup>c</sup> The positivity rate was higher for women (Pearson Chi-square p<0.0001) and the median age for women testing positive (28) was lower than for positive men (30; Kruskal-Wallis p=0.023). 
Table 3: Distribution of N1 and N3 Ct Values for Unobserved Self-Collected (SC) and Health Care Provider-Collected (HCP) SARS-CoV-2 Positive Specimens

| Group | Indicated | Symptomatic\(^a\) | Period       | Target | \(N\)\(^b\) | Median (IQR) Ct | \(\geq\)shifted Ct | \(N\) (%)\(^c\) |
|-------|-----------|--------------------|--------------|--------|------------|----------------|-------------------|-----------------|
| SC    | NA        |                    | 6.3.20-      | N1     | 1,268      | 32.7           | (25.1-35.7)      | 67 (5.3)        |
|       |           |                    | 8.12.20      | N3     | 1,268      | 31.3           | (24.0-34.2)      | 1 (0.08)        |
| HCP   | NA        |                    | 6.3.20-      | N1     | 28,039     | 23.6           | (17.4-30.8)      | 293 (1.0)       |
|       |           |                    | 8.12.20      | N3     | 28,039     | 22.5           | (16.6-29.5)      | 19 (0.07)       |
|       | Yes       |                    | 3.24.20-     | N1     | 4,137      | 23.9           | (17.5-33.0)      | 261 (6.3)       |
|       |           |                    | 5.13.20      | N3     | 2,753      | 22.9           | (16.8-31.4)      | 4 (0.15)        |
|       | No        |                    | 3.24.20-     | N1     | 421        | 30.6           | (22.0-36.4)      | 39 (9.3)        |
|       |           |                    | 5.13.20      |        |            |                |                   |                 |
|   |   |   |   |
|---|---|---|---|
| N3 | 357 | 29.8 | 0 (0.0) |
|   |   | (22.2-34.9) |   |

\(^a\) Client-reported prompted analyte that was optionally entered at the time of SARS-CoV-2 RT-PCR test order submission. Its use was discontinued in May 2020.

\(^b\) Number of results available for the N1 and N3 targets. Prior to April 2020, the N1 and N2, but not the N3 targets were used in determining the test result. The age range for HCP collected patients was set at 18-78 to match the age range for SC patients.

\(^c\) The number of specimens with a Ct value greater than or equal to the pool-shifted Ct values of 37.6 (N1) and 38.1 (N3) as described in Materials and Methods

\(^d\) NA: Not Available
Figure Legends

**Figure 1:** Ct value distributions for the N1 target (A) and N3 target for patients (n=234) with two or more positive SARS-CoV-2 RT-PCR test results. First N1, N3: Ct values from the first positive test. Last N1, N3: paired Ct values for the last positive test. The differences between the first and the last Ct value distributions were significant (Wilcoxon, p<0.0001).
